Straumann Group (STMN) Q3 2024 earnings summary

Executive summary

• Achieved strong organic revenue growth of 11.2% in Q3, reaching CHF 586 million, and 14.5% for the first nine months, totaling CHF 1.9 billion.

• Gained market share globally, with EMEA (11.4%), APAC (19.7%), and LATAM (18.9%) delivering double-digit growth; North America grew but faced macroeconomic headwinds.

• Launched new digital solutions, including the global launch of the Straumann/SIRIOS intraoral scanner and pre-launch of iExcel premium implant system.

• Continued significant investments in manufacturing capacity, notably a new Neodent factory in Brazil and expansion in China.

• Confirmed full-year 2024 outlook for low double-digit organic revenue growth and profitability in the 27%-28% range at constant 2023 currency rates.

Financial highlights

• Q3 organic revenue growth of 11.2% (CHF 585.5–586 million); nine-month organic growth of 14.5% (CHF 1.9 billion).

• EMEA contributed CHF 216.4 million in Q3 (11.4% organic growth); APAC CHF 149.4 million (19.7%); LATAM CHF 56.8 million (18.9%); NAM CHF 162.9 million (2.0%).

• FX headwinds reduced top line by CHF 85 million (approx. 5% impact); M&A contributed CHF 21 million.

• Adjusted nine-month revenue base at CHF 1.6 billion.

• FX sensitivity: +/-10% change in major currencies impacts revenue by CHF 12m–48m.

Outlook and guidance

• Confident in achieving low double-digit organic revenue growth and 27%-28% profitability for 2024 at constant currency.

• Growth ambition for 2030 reaffirmed, with a focus on expanding market leadership and digital transformation.

• No significant change expected in Q4 dynamics; robust trends anticipated in EMEA, Asia Pacific, and Latin America.

• North America expected to improve as interest rates decline, with further clarity on 2025 outlook after Q4.

• Management remains confident in gaining market share despite geopolitical and macroeconomic uncertainties.